Sign in to view content

Treatment Response to Antioxidant Supplementation Based on CFH and ARMS2Â Genetic Risk Allele Number in AREDS Patients With No AMD at Baseline

Carl C. Awh, MD, FASRS

Video
Published 2016

Related

The OASIS Trial: Efficacy and Safety Outcomes in Subjects With Full-Thickness Macular Hole
Michael Tolentino, MD
Annual Meeting Talks
2016
“Real World” U.S. Outcomes of Anti-VEGF Therapy in Neovascular AMD: Risk of Vision Loss is Greatest in Patients with Better Baseline Visual Acuity
Thomas A. Ciulla, MD, MBA, FASRS
Annual Meeting Talks
2016
Optical Coherence Tomography Angiography in Patients With Cystoid Macular Edema Associated With Retinitis Pigmentosa
Young Hee Yoon, MD, PhD
Annual Meeting Talks
2019

Category: AMD-Non-Neovascular

See more